Stoke Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive income (loss)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $158,569 | $4,216 |
| Operating expenses: | ||
| Research and development | 32,676 | 22,368 |
| General and administrative | 14,653 | 10,220 |
| Total operating expenses | 47,329 | 32,588 |
| Income (loss) from operations | 111,240 | (28,372) |
| Other income (expense): | ||
| Interest income (expense), net | 2,889 | 2,426 |
| Other income (expense), net | 28 | (428) |
| Total other income (expense) | 2,917 | 1,998 |
| Income (loss) before income taxes | $114,157 | $(26,374) |
| Provision for income taxes | 1,278 | — |
| Net income (loss) | $112,879 | $(26,374) |
| Net income (loss) per share: | ||
| Basic | $1.95 | $(0.57) |
| Diluted | 1.90 | (0.57) |
| Weighted-average common shares outstanding: | ||
| Basic | 57,862,674 | 46,246,889 |
| Diluted | 59,398,600 | 46,246,889 |
| Comprehensive income (loss): | ||
| Net income (loss) | $112,879 | $(26,374) |
| Other comprehensive gain: | ||
| Unrealized gain on marketable securities | 47 | 24 |
| Total other comprehensive gain | $47 | $24 |
| Comprehensive income (loss) | $112,926 | $(26,350) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.